Cannabis Science Announces its Attendance at KushCon -the World's Largest Cannabis Lifestyle Convention - Speaking Engagement by Dr. Robert Melamede and Company Display Booth
DENVER, Dec. 15, 2010 /PRNewswire/ -- Cannabis Science, Inc. (OTC Bulletin Board: CBIS), a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to announce that Dr. Robert Melamede , Cannabis Science CEO, will be speaking at KushCon (http://www.kushcon.com) Convention in Denver, CO. This event will be the largest cannabis industry event in human history and takes place from December 17-19, 2010. Dr. Melamede will focus his speech on 'Cannabis prohibition and the biology of the American Taliban'.
Cannabis Science will have a display and information booth at KushCon to inform investors and patients regarding the Company's stock and listings, medical cannabis products, delivery systems, FDA trials and other important information. Please be sure to stop by to say hello and learn more about Cannabis Science and how you can get involved to change the world!
Dr. Robert Melamede , Cannabis Science CEO said that, "KushCon is a great forum to discuss critical issues with medical marijuana legalization and how to satisfy the needs of patients. I'm excited for the opportunity to shed more light on why prohibition extremists are holding patients captive by restricting their access to medical cannabis. For modern main, cannabis is an essential nutrient that improves quality of life, minimizes pain and suffering, and provides people with a natural, holistic alternative to often deadly man-made pharmaceuticals. The proof is in the statistics; medical cannabis has never kill a single person in recorded history while conventional pharmaceuticals kill over one hundred thousand Americans each year. Add to that figure hundreds of thousand killed each year from alcohol and tobacco-related illnesses. Any intelligent, open-minded person can see the need for change"
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements
Forward Looking Statements; This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Cannabis Science Inc.
Dr. Robert J. Melamede
President & CEO
Cannabis Science Inc.
Mark J. Friedman
SOURCE Cannabis Science, Inc.
More by this Source
Cannabis Science announces preclinical development program for CS-TATI-I, commencing EU operations in the Netherlands and sourcing proprietary material for pharmacokinetic characterization
Apr 26, 2013, 09:28 ET
Cannabis Science, Inc. Appoints Michael McGrath, MD, PhD, Professor, Departments of Laboratory Medicine, Pathology, and Medicine, UCSF, and Co-Founder of Biotechs Pathologica LLC and Neuraltus Pharmaceuticals, to the Company's Scientific Advisory Bo
Mar 27, 2013, 12:41 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.